Chris Illiades, MD

New research suggests that fibromyalgia is primarily a peripheral nerve disorder that causes central nervous system sensitization.

The role of GCH1 mutations in Parkinson’s disease is complicated by the mutation’s seemingly exclusive role in dopa-responsive dystonia.

The role of teleneurology can grow far beyond critical stroke care, but only if medical liabilities and insurance steps out of the way.

Vestibular migraine may have finally won its own diagnostic criteria, but the condition is still shrouded in uncertainties.

With no established guidelines, much of the decisions for management of hypertension during stroke are based on clinician experience.

Vitamin D deficiency is known to contribute to neurodegenerative diseases like dementia, however its connection to ALS is not yet well understood.

Closed-loop neurostimulation technology is being investigated for movement disorders, headache, and even some neuropsychiatric disorders.

A personalized approach to treating epileptic seizures ensures a balance of effectiveness and tolerability for each patient.

While new technology is making it more accessible, the clinical applications of genome sequencing are still being explored.

Motion-sensing technology provides a lot of data, but researchers still aren’t sure if it’s clinically useful.

The medical community is taking steps to clarify delirium pathology and diagnosis.

Robotics, stem cell therapy, and computer-controlled interfaces are promising, but cost may slow adoption.

Advanced imaging technologies to monitor multiple sclerosis (MS) are being developed but have been plagued by high costs and invasive procedures.

If the UTHealth mobile stroke unit program can show that treating ischemic stroke within 60 minutes is feasible and cost effective, more may start rolling out nationally.

Research to enhance understanding of SUDEP biology is critical for discovering clinical and molecular biomarkers that could help identify at-risk patients.

Developing drugs that selectively block specific sodium channels could be the holy grail of neuropathic pain treatment.

Genetically-engineered CGRP antibodies have proven effective in initial trials at reducing migraine days.